/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

R

Ruth O’Regan

University College Dublin(IE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

277

Papers

15.7K

Citations

55

h-index

105

i10-index

Ruth O’Regan is an academic researcher from University College Dublin. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 55, co-authored 236 publications.

ORCID: 0000-0001-6984-3741

Research Topics

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Estrogen and related hormone effects

Papers by this author

works

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

2020 · Journal of Clinical Oncology · 529 citations

https://doi.org/10.1200/jco.20.00775

Nancy U. Lin Virginia F. Borges Carey K. Anders Rashmi K. Murthy

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · The Lancet Oncology · 379 citations

https://doi.org/10.1016/s1470-2045(17)30688-5

Angelo Di Leo Stephen Johnston Keun Seok Lee Eva Ciruelos

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

2023 · Journal of Clinical Oncology · 173 citations

https://doi.org/10.1200/jco.22.02392

Kevin Kalinsky Melissa Accordino Codruța Chiuzan Prabhjot S. Mundi

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

2016 · Journal of Clinical Oncology · 165 citations

https://doi.org/10.1200/jco.2015.63.9161

Fabrice André Sara A. Hurvitz Angelica Fasolo Ling‐Ming Tseng

Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells

2011 · Molecular Cancer Therapeutics · 102 citations

https://doi.org/10.1158/1535-7163.mct-10-0925

Tongrui Liu Rami Yacoub LaTonia Taliaferro‐Smith Shi‐Yong Sun

Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway

2010 · Clinical Breast Cancer · 93 citations

https://doi.org/10.3816/cbc.2010.s.015

Rita Nahta Ruth O’Regan

Research topics

topics

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

Cancer Treatment and Pharmacology

HER2/EGFR in Cancer Research

Estrogen and related hormone effects

Chat about Author

Papers

Chat

Click to start Chat